As of 1st March 2026, Glofitamab (brand name COLUMVI®) is now listed on the PBS in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of adults with diffuse large B-cell lymphoma (DLBCL) whose cancer has returned after initial treatment and who are not eligible for a stem cell transplant.
Glofitamab (COLUMVI®) is a bispecific antibody treatment. It is now available on the Pharmaceutical Benefits Scheme (PBS) in Australia for people with Refractory or Relapsed Diffuse Large B-cell Lymphoma (DLBCL) who are not eligible for a stem cell transplant.
Refractory means the lymphoma is not responding to treatment, it may be staying the same or getting worse even with treatment. Relapsed means the treatment initially worked well and you went into remission, but the lymphoma has come back.
Patients living with DLBCL and their families should discuss treatment options with their specialist. Refer to the Consumer Medicine Information or speak to your haematologist for further information.
What are Bispecific Antibodies?
Bispecific antibodies are medicines made from antibodies created in a laboratory that can attach to 2 different targets at the same time. It attaches to T-cells (a type of disease fighting immune cell) AND to lymphoma cells. This brings the T-cell close to the lymphoma and by doing this, it helps your immune system find and destroy the lymphoma.
Bi-specific antibodies help boost your body’s natural ability to fight DLBCL. For more information on how these work, visit: Bispecific Antibodies & Antibody Conjugates.
